Results 231 to 240 of about 147,755 (251)
Some of the next articles are maybe not open access.
Anti-obesity drugs for the gastroenterologist
Frontline GastroenterologyGlucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used in the management of diabetes mellitus and obesity and have become accessible to many through non-standard prescribing pathways. Studies are demonstrating a plethora of positive effects on cardiovascular health, renal disease and liver disease, which may be directly related to ...
openaire +1 more source
Anti‐obesity drugs: to be or not to be?
Obesity Reviews, 2010Dvorak, R.V., Sharma, A.M., Astrup, Arne
openaire +3 more sources
Anti-Obesity Drugs: are They Worth It?
Future Medicinal Chemistry, 2011Mark K, Huntington, Roger A, Shewmake
openaire +2 more sources
First do no harm with anti-obesity and other drugs
BMJ, 2013On the issue of obesity,1 we welcome the decision by the European Medicines Agency to refuse marketing authorisation for the fixed dose combination of topiramate (an antiepileptic) and phentermine (an appetite suppressant amphetamine).2 The loss of a few kilograms cannot justify …
openaire +2 more sources
[Action mechanisms of anti-obesity drugs].
Nihon rinsho. Japanese journal of clinical medicine, 2009Principle of the treatment of obesity is diet and exercise therapy. However, it is extremely difficult to maintain the effect in the long term. In recent years, mechanism of appetite center and adaptive thermogenesis is gradually clarified. As a tool of new treatment of obesity, anti-obesity drugs come to attract attention in this way.
Daiji, Nagayama, Kohji, Shirai
openaire +1 more source
FDA-Approved Anti-Obesity Drugs in the United States
American Journal of Medicine, 2016Gerald W Smetana, Mark D Aronson
exaly